For high VEGF-Axxxa , the hazard ratios ( HRs ) for progression were @ ( P = @ ) in non-bevacizumab-treated patients ( cohort A ) and @ ( P = @ ) in bevacizumab-treated patients ( cohort B ) , and the HRs for death were @ ( P = @ ) and @ ( P = @ ) , respectively .